Progress in HIV vaccine development

Hum Vaccin Immunother. 2017 May 4;13(5):1018-1030. doi: 10.1080/21645515.2016.1276138. Epub 2017 Mar 10.


An HIV-1 vaccine is needed to curtail the HIV epidemic. Only one (RV144) out of the 6 HIV-1 vaccine efficacy trials performed showed efficacy. A potential mechanism of protection is the induction of functional antibodies to V1V2 region of HIV envelope. The 2 main current approaches to the generation of protective immunity are through broadly neutralizing antibodies (bnAb) and induction of functional antibodies (non-neutralizing Abs with other potential anti-viral functions). Passive immunization using bnAb has advanced into phase II clinical trials. The induction of bnAb using mimics of the natural Env trimer or B-cell lineage vaccine design is still in pre-clinical phase. An attempt at optimization of protective functional antibodies will be assessed next with the efficacy trial (HVTN702) about to start. With on-going optimization of prime/boost strategies, the development of mosaic immunogens, replication competent vectors, and emergence of new strategies designed to induce bnAb, the prospects for a preventive HIV vaccine have never been more promising.

Keywords: HIV; RV144; broadly neutralizing antibodies; functional antibodies; vaccine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • AIDS Vaccines / adverse effects
  • AIDS Vaccines / chemistry
  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Antibodies, Neutralizing / biosynthesis*
  • Antibodies, Neutralizing / immunology*
  • B-Lymphocytes / immunology
  • Clinical Trials as Topic
  • HIV Antibodies / biosynthesis*
  • HIV Antibodies / immunology*
  • HIV Envelope Protein gp120 / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV-1 / immunology
  • Humans
  • Immunization, Passive


  • AIDS Vaccines
  • Antibodies, Neutralizing
  • HIV Antibodies
  • HIV Envelope Protein gp120